PAVmed Inc. (PAVM): Price and Financial Metrics

PAVmed Inc. (PAVM): $9.39

1.18 (+14.37%)

POWR Rating

Component Grades













PAVM Stock Price Chart Interactive Chart >

Price chart for PAVM

PAVM Price/Volume Stats

Current price $9.39 52-week high $9.70
Prev. close $8.21 52-week low $1.63
Day low $8.62 Volume 6,202,237
Day high $9.70 Avg. volume 3,080,070
50-day MA $7.05 Dividend yield N/A
200-day MA $4.86 Market Cap 795.97M

PAVmed Inc. (PAVM) Company Bio

PAVmed Inc. operates as a medical device company in the United States. Its product pipeline includes PortIO, a long-term implantable vascular access device; CarpX, a percutaneous device to treat carpal tunnel syndrome; NextCath, a self-anchoring catheter; DisappEAR: Antibiotic-eluting resorbable ear tube; NextFlo, a disposable infusion pump; and Caldus, a disposable tissue ablation device. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was founded in 2014 and is based in New York, New York.

PAVM Latest News Stream

Event/Time News Detail
Loading, please wait...

PAVM Latest Social Stream

Loading social stream, please wait...

View Full PAVM Social Stream

Latest PAVM News From Around the Web

Below are the latest news stories about PAVmed Inc that investors may wish to consider to help them evaluate PAVM as an investment opportunity.

PAVmed Subsidiary Veris Health Joins Microsoft for Startups Global Program and Engages Loka as Software Development Partner

NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed subsidiary Veris Health joins Microsoft for startups global program and engages Loka as software development partner.

Business Wire | September 21, 2021

The Daily Biotech Pulse: MacroGenics'' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA''s FDA Nod

Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc. (NASDAQ: ADIL ) Axonics, Inc. (NASDAQ: AXNX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Candel Therapeutics, Inc. (NASDAQ: CADL ) (announced completion of patient enrollment in the pivotal phase 3 study of CAN-2409 in prostate cancer) Cardiol Therapeutics Inc. (NASDAQ: CRDL ) (announced addition to its board) Caribou Biosciences, Inc. (NASDAQ: CRBU ) Catalent, Inc. (NASDAQ: CTLT ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) Edwards Lifesciences Corporation (NYSE: EW ) Er...

Benzinga | September 8, 2021

PAVmed to Participate in September Investor and MedTech Conferences

NEW YORK, September 07, 2021--PAVmed to participate in September investor and MedTech conferences.

Yahoo | September 7, 2021

Why Shares of PAVmed Were Down This Morning

Investors are growing impatient about a planned spinoff.

The Motley Fool | August 13, 2021

PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results

NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results. Conference call to be held today at 4:30 PM EDT.

Business Wire | August 12, 2021

Read More 'PAVM' Stories Here

PAVM Price Returns

1-mo 35.89%
3-mo 39.94%
6-mo 125.18%
1-year 418.78%
3-year 633.59%
5-year N/A
YTD 342.92%
2020 76.67%
2019 24.74%
2018 -57.90%
2017 -66.88%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.867 seconds.